Sandoz: EU approves Bayer's generic version of Eylea

(CercleFinance.com) - Sandoz announced on Friday that the European Commission had decided to authorize its generic version of Eylea, Bayer's treatment for the neovascular form of age-related macular degeneration (AMD).


This biosimilar, called 'Afqlir' - which comes in a 2 mg pre-filled syringe - should be on the market by the end of the year, says the pharmaceutical company.

AMD - which leads to progressive alteration of the retina - is the leading cause of vision loss in the elderly.

Sandoz specifies that the green light from Brussels will also apply to Eylea's other ocular indications linked to reduced visual acuity.


Copyright (c) 2024 CercleFinance.com. All rights reserved.